Affordable purification Proteios offers a patented dodecapeptide affinity tag that enables low-cost, high-throughput protein purification with yields over 15 mg and purity above 90%, presenting a clear value proposition for CROs and biopharma partners seeking cost-efficient scale-up solutions.

High throughput capability The platform supports automated protein manipulations, microtiter-based HTS purification, and chip printing for HTS, making Proteios an attractive partner for companies pursuing rapid screening, parallel purification workflows, and scalable assay development.

Safety and compliance Emphasizing biologically-safe reagents and absence of heavy-metal impurities positions Proteios well for collaborations in regulated spaces, including clinical-grade protein production and cellular therapy applications where safety profiles are critical.

Strategic fit with big players Competitive landscape shows alignment with large lifecycle players (e.g., QIAGEN, Thermo Fisher) seeking innovative purification tech to supplement existing portfolios, suggesting partnership or licensing discussions could unlock distribution and scale benefits.

Growth signals With revenue in the low-mid millions and a focused technology platform, Proteios appears poised for targeted funding rounds or strategic partnerships to accelerate product kits, expand capabilities, and broaden market reach in protein purification and related biotech workflows.